Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...
Waukegan D60 joining suit to recover insulin charges; ‘No rhyme or reason for these increases other than price-gouging’
The District 60 Board of Education unanimously approved a resolution hiring the Frantz Law Group Tuesday at the Lincoln Center administration building in Waukegan to help it recoup some of the ...
The Pharma Letter1d
Sanofi investing 40 million euros on expanding Lyon Gerland site
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
MSCS joins 'mass action' suit against drug companies over insulin costs
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
The Punch Newspapers1d
Experts decry diabetes drugs cost as patients reach 14m
Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...
Bedford Citizen1d
Dr. Meijing Wu Remembered as Scientist, Mentor, and Friend
Dr. Meijing Wu is described by friends and colleagues as a distinguished biostatistician and “a kind and generous friend who ...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with ...
GEN2d
AI Collaboration Between Sanofi and Healx Will Target Novel Rare Diseases Indications
Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...
HHS Must End Unauthorized Administration Of 340B Drug-Discount Program
Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...